腫瘍溶解性ウイルス療法の世界市場

腫瘍溶解性ウイルス療法の世界市場は2030年までに4,520万米ドルに達する見込み

2024年に1,380万米ドルと推定される腫瘍溶解性ウイルス療法の世界市場は、2030年には4,520万米ドルに達し、分析期間2024-2030年のCAGRは21.8%で成長すると予測されます。本レポートで分析したセグメントの1つである単純ヘルペスウイルスは、20.8%のCAGRを記録し、分析期間終了時には1,180万米ドルに達すると予測されます。アデノウイルス分野の成長率は、分析期間中CAGR 19.2%と推定されます。

米国市場は380万米ドルと推定、中国はCAGR29.0%で成長すると予測

米国の腫瘍溶解性ウイルス療法市場は、2024年に380万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR29.0％を牽引し、2030年には予測市場規模1,070万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.7％と19.5％と予測されています。欧州では、ドイツがCAGR約18.3%で成長すると予測されています。

世界の腫瘍溶解性ウイルス療法市場- 主要動向と促進要因のまとめ

遺伝子組み換えウイルスはがん免疫療法の次のフロンティアになるか？

腫瘍溶解性ウイルス療法（OVT）は、遺伝子操作された、あるいは天然に存在するウイルスを利用して、正常組織を温存しながらがん細胞に選択的に感染し破壊する、がん治療への最先端のアプローチです。腫瘍内に入ると、これらのウイルスは複製され、免疫原性の細胞死を誘導し、全身の抗腫瘍免疫応答を刺激します。この直接的なオンコライシスと免疫活性化という2つの作用機序により、OVTは標的療法と免疫療法の間の有望な橋渡し役として位置づけられ、固形がんや血液悪性腫瘍への応用が期待されています。

進行性黒色腫に対するHSV-1ベースの治療薬であるImlygic（Talimogene laherparepvecまたはT-VEC）が承認された後、OVTに対する臨床的および前臨床的関心が急上昇しました。それ以来、アデノウイルス、レオウイルス、ワクシニアウイルス、麻疹ウイルス、コクサッキーウイルスに基づくOVT候補のパイプラインが、膠芽腫、膵臓がん、結腸直腸がん、肺がんなど、さまざまながん適応症で評価されつつあります。合成生物学、腫瘍標的リガンド、免疫調節遺伝子挿入の進歩は、オンコルトウイルスの特異性と効力をさらに高め、免疫チェックポイント阻害剤、CAR-T細胞、放射線療法との理想的な併用パートナーとなっています。

なぜ併用療法戦略は臨床情勢を一変させるのか？

腫瘍溶解性ウイルスの単剤療法は、腫瘍の種類によってはそこそこの有効性を示しています。しかし、その最大の治療可能性は、他の免疫腫瘍学（IO）薬剤との併用で実現されつつあります。OVTは腫瘍微小環境（TME）を再プログラムし、免疫排除を克服し、T細胞浸潤を改善することができ、PD-1/PD-L1チェックポイント阻害剤と併用すると相乗効果が得られます。現在、OVTを抗CTLA-4、CAR-NK療法、サイトカイン療法、二重特異性抗体と併用し、特に既存のIOレジメンに抵抗性を示す免疫学的に"冷たい"腫瘍で評価する複数の試験が進行中です。

この分野における重要な動向は、サイトカイン（GM-CSF、IL-12）、免疫チェックポイント阻害剤、あるいは腫瘍関連抗原をコードする導入遺伝子を発現するようにOVを工学的に設計し、免疫原性を高めた多機能性ウイルス療法を作り出すことです。これらの次世代プラットフォームは、奏効率を高めるだけでなく、腫瘍特異的選択性を改善し、全身毒性を軽減し、個別化医療戦略を可能にします。規制当局の環境整備が進み、試験デザインの適応性が高まるにつれ、OVTは次世代免疫療法パイプラインの要としてますます注目されるようになっています。

技術革新とデリバリー・プラットフォームはどのように市場リーチを拡大しているのか？

OVT開発における大きな課題の一つは、効率的なデリバリーと免疫回避です。腫瘍内注入は、アクセス可能な病変には有効であるが、より広い範囲への適用には限界があります。ウイルス遮蔽、間葉系幹細胞などのキャリア細胞を用いた送達、ナノ粒子カプセル化など、全身的な送達方法における最近の進歩は、中和抗体や臓器特異的封じ込めの障壁を克服するのに役立っています。これらの送達戦略は、OVTを転移性腫瘍や深在性腫瘍にまで拡大することを目指しています。

さらに、CRISPR-Cas9のような遺伝子編集ツールは、より優れた安全性、腫瘍向性、ペイロード制御のためにウイルスゲノムを微調整するために使用されています。開発企業は、複製動態、免疫活性化、ベクターの安定性を最適化したウイルス変異体の迅速な設計と試験が可能なモジュール式OVTプラットフォームを開発しています。さらに、AI主導の薬剤設計とデジタル病理学によって、患者の層別化と予測バイオマーカー発見が改善され、精密腫瘍学においてOVTをより的を絞った効果的な利用が可能になっています。

腫瘍溶解性ウイルス療法市場の成長を後押ししているのは？

腫瘍溶解性ウイルス療法市場の成長の原動力は、がん罹患率の上昇、従来の治療法に対する抵抗性の増加、OVTメカニズムの臨床的検証の拡大です。主な成長要因は、次世代免疫療法に焦点を当てたバイオテクノロジー企業、製薬大手、研究コンソーシアムによる投資の活発化です。リプリミューン、オンコリティクス・バイオテック、シラジェン、CGオンコロジー、ローコン・ファーマなど、OVTプラットフォームを開発する企業には、戦略的パートナーシップ、ライセンシング契約、ベンチャーキャピタルからの資金が注ぎ込まれています。

さらに、治療が困難ながんに対するOVTのファスト・トラックや希少疾病用医薬品指定が認められるなど、規制当局の機運も高まっています。特に北米、欧州、東アジアでは、政府が支援するがん撲滅プログラム（moonshot program）や産学連携が試験活動を加速させています。免疫腫瘍学、ウイルス学、合成生物学が融合することで、初回治療と難治性治療の両方においてOVTの道が開かれ、選択肢が限られている患者に新たな希望がもたらされています。

送達システムが改善され、臨床データが成熟し、商業的インフラが強化されるにつれて、腫瘍溶解性ウイルス療法はニッチな実験的治療法から主流のがん治療法へと進化する態勢が整っています。局所的な腫瘍破壊と全身的な免疫刺激を組み合わせるユニークな能力を持つOVTは、腫瘍学の治療パラダイムを再定義する可能性を秘めています。

セグメント

製品タイプ（単純ヘルペスウイルス、アデノウイルス、ワクシニアウイルス、レオウイルス、麻疹ウイルス、その他の製品タイプ）、用途（黒色腫、乳がん、頭頸部がん、膀胱がん、前立腺がん、肺がん、その他の用途）、開発段階（商業段階、パイプライン段階）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（全36件）

• Akamis Bio
• Amgen Inc.
• Calidi Biotherapeutics
• Candel Therapeutics
• CG Oncology
• Genelux Corporation
• Imugene Limited
• Lokon Pharma AB
• Oncolys BioPharma Inc.
• Oncolytics Biotech Inc.
• Replimune Group Inc.
• SillaJen, Inc.
• Theolytics Ltd.
• Theriva Biologics
• TILT Biotherapeutics Ltd.
• Transgene S.A.
• Turnstone Biologics Corp.
• Valo Therapeutics Ltd.
• VCN Biosciences S.L.
• Vyriad, Inc.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Oncolytic Virus Therapy Market to Reach US$45.2 Million by 2030

The global market for Oncolytic Virus Therapy estimated at US$13.8 Million in the year 2024, is expected to reach US$45.2 Million by 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. Herpes Simplex Virus, one of the segments analyzed in the report, is expected to record a 20.8% CAGR and reach US$11.8 Million by the end of the analysis period. Growth in the Adenovirus segment is estimated at 19.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Million While China is Forecast to Grow at 29.0% CAGR

The Oncolytic Virus Therapy market in the U.S. is estimated at US$3.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.7 Million by the year 2030 trailing a CAGR of 29.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.7% and 19.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 18.3% CAGR.

Global Oncolytic Virus Therapy Market - Key Trends & Drivers Summarized

Could Engineered Viruses Become the Next Frontier in Cancer Immunotherapy?

Oncolytic virus therapy (OVT) represents a cutting-edge approach to cancer treatment that harnesses genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal tissues. Once inside the tumor, these viruses replicate, induce immunogenic cell death, and stimulate systemic anti-tumor immune responses-effectively turning the tumor into its own vaccine. This dual mechanism of action-direct oncolysis and immune activation-positions OVT as a promising bridge between targeted therapy and immunotherapy, with applications in solid tumors and hematologic malignancies.

Clinical and preclinical interest in OVT has surged following the regulatory approval of Imlygic (Talimogene laherparepvec or T-VEC), an HSV-1 based therapy for advanced melanoma. Since then, a growing pipeline of OVT candidates based on adenoviruses, reoviruses, vaccinia, measles, and coxsackieviruses is being evaluated across various cancer indications, including glioblastoma, pancreatic, colorectal, and lung cancers. Advances in synthetic biology, tumor-targeting ligands, and immune-modulatory gene insertion are further enhancing the specificity and potency of oncolytic viruses, making them ideal combination partners with immune checkpoint inhibitors, CAR-T cells, and radiotherapy.

Why Is Combination Therapy Strategy Transforming the Clinical Landscape?

Monotherapy with oncolytic viruses has shown modest efficacy in some tumor types; however, their greatest therapeutic potential is being realized in combination with other immuno-oncology (IO) agents. OVTs can reprogram the tumor microenvironment (TME), overcome immune exclusion, and improve T-cell infiltration-creating a synergistic effect when used alongside PD-1/PD-L1 checkpoint inhibitors. Multiple trials are currently underway to evaluate OVT in combination with anti-CTLA-4, CAR-NK therapies, cytokine therapies, and bispecific antibodies, especially in immunologically “cold” tumors that are resistant to existing IO regimens.

A key trend in the field is the engineering of OVs to express transgenes that encode for cytokines (GM-CSF, IL-12), immune checkpoint inhibitors, or tumor-associated antigens, creating multi-functional virotherapies with enhanced immunogenicity. These next-generation platforms are not only increasing response rates but also improving tumor-specific selectivity, reducing systemic toxicity, and enabling personalized medicine strategies. As the regulatory environment becomes more supportive and trial designs more adaptive, OVT is increasingly seen as a cornerstone of next-wave immunotherapy pipelines.

How Are Technological Innovations and Delivery Platforms Expanding Market Reach?

One of the major challenges in OVT development has been efficient delivery and immune evasion. Intratumoral injection, while effective for accessible lesions, limits broader applicability. Recent advances in systemic delivery methods-including virus shielding, carrier cell-based delivery (e.g., mesenchymal stem cells), and nanoparticle encapsulation-are helping overcome the barriers of neutralizing antibodies and organ-specific sequestration. These delivery strategies aim to extend OVT to metastatic and deep-seated tumors.

Moreover, gene editing tools such as CRISPR-Cas9 are being used to fine-tune viral genomes for better safety, tumor tropism, and payload control. Companies are developing modular OVT platforms capable of rapid design and testing of virus variants with optimized replication kinetics, immune activation, and vector stability. Additionally, AI-driven drug design and digital pathology are improving patient stratification and predictive biomarker discovery, enabling more targeted and effective use of OVT in precision oncology.

What’s Fueling the Growth of the Oncolytic Virus Therapy Market?

The growth in the oncolytic virus therapy market is driven by rising cancer incidence, increasing resistance to conventional therapies, and expanding clinical validation of OVT mechanisms. A primary growth driver is the intensifying investment by biotech companies, pharmaceutical giants, and research consortia focused on next-generation immunotherapies. Strategic partnerships, licensing deals, and venture capital funding are pouring into companies developing OVT platforms, including Replimune, Oncolytics Biotech, SillaJen, CG Oncology, and Lokon Pharma.

Additionally, regulatory momentum is building, with fast-track and orphan designations being granted for OVTs in hard-to-treat cancers. Government-backed cancer moonshot programs and academic-industry collaborations are accelerating trial activity, particularly in North America, Europe, and East Asia. The convergence of immune-oncology, virology, and synthetic biology is opening avenues for OVT in both first-line and refractory settings, offering new hope for patients with limited options.

As delivery systems improve, clinical data matures, and commercial infrastructure strengthens, oncolytic virus therapy is poised to evolve from a niche experimental modality into a mainstream cancer treatment. With its unique ability to combine localized tumor destruction and systemic immune stimulation, OVT holds the potential to redefine therapeutic paradigms in oncology.

SCOPE OF STUDY:

The report analyzes the Oncolytic Virus Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus, Other Product Types); Application (Melanoma, Breast Cancer, Head & Neck Cancer, Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications); Development Stage (Commercial, Pipeline Phase); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Akamis Bio
• Amgen Inc.
• Calidi Biotherapeutics
• Candel Therapeutics
• CG Oncology
• Genelux Corporation
• Imugene Limited
• Lokon Pharma AB
• Oncolys BioPharma Inc.
• Oncolytics Biotech Inc.
• Replimune Group Inc.
• SillaJen, Inc.
• Theolytics Ltd.
• Theriva Biologics
• TILT Biotherapeutics Ltd.
• Transgene S.A.
• Turnstone Biologics Corp.
• Valo Therapeutics Ltd.
• VCN Biosciences S.L.
• Vyriad, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Oncolytic Virus Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Emphasis on Precision Immuno-Oncology Therapies Drives Adoption of Oncolytic Virus Modalities
  • Expansion of Clinical Trials Across Multiple Tumor Types Throws the Spotlight on Versatile Oncolytic Platforms
  • OEM Innovation in Armed Oncolytic Vectors Strengthens Therapeutic Potency and Tumor Specificity
  • Regulatory Support for Breakthrough and Fast-Track Approvals Accelerates Time-to-Market for OV Candidates
  • Increased Collaboration Between Biotech Firms and Academic Research Centers Enhances Pipeline Diversity
  • Integration of Oncolytic Viruses With Checkpoint Inhibitors Supports Synergistic Immunotherapy Strategies
  • Growth in Intratumoral and Systemic Delivery Technologies Expands Treatable Cancer Sites
  • OEM Focus on Genetic Engineering of Viral Backbones Enhances Safety Profiles and Immune Stimulation
  • Emergence of Personalized Oncolytic Therapies Tailored to Tumor Microenvironments Expands Application Scope
  • Rising Investor Interest in Novel Modalities Spurs M&A Activity and Venture Capital Funding in OV Biotech
  • Use in Solid Tumors With Limited Therapeutic Options Strengthens Business Case in Unmet Needs Segment
  • Challenges in Anti-Viral Immune Response and Neutralization Drive Innovation in Shielding Technologies
  • Expansion of Viral Manufacturing Capabilities Supports Clinical and Commercial Scalability of OV Pipelines
  • OEM Partnerships With CDMOs and Viral Vector Platforms Enhance Process Development and GMP Readiness
  • Focus on Minimizing Off-Target Effects Propels Research Into Next-Gen Selective Viral Activation Mechanisms
  • Growing Interest in OV Therapies for Rare and Pediatric Tumors Opens Orphan Drug Development Pathways
  • Development of Biomarkers for Response Prediction Enhances Patient Selection and Trial Success
  • Global Support for Cancer Moonshot and Public Funding Initiatives Strengthens Basic OV Research Ecosystem
  • OEM Integration of Imaging and Companion Diagnostics Supports Monitoring and Combination Therapy Planning
  • Regulatory Harmonization Across U.S., EU, and Asia Facilitates Global Trial Expansion and Parallel Submissions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Oncolytic Virus Therapy Market Analysis of Annual Sales in US$ for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Oncolytic Virus Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Vaccinia Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Vaccinia Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Reovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Reovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Measles Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Measles Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Measles Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Head & Neck Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Pipeline Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Pipeline Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Pipeline Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 95: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Oncolytic Virus Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 122: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 157: Italy 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 158: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 169: UK 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 181: Spain 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 193: Russia 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 232: Australia 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 233: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 244: India 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 256: South Korea 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Oncolytic Virus Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 283: Latin America 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 295: Argentina 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 307: Brazil 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 319: Mexico 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Oncolytic Virus Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 346: Middle East 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 358: Iran 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 370: Israel 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 394: UAE 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Oncolytic Virus Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Oncolytic Virus Therapy by Product Type - Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Oncolytic Virus Therapy by Product Type - Percentage Breakdown of Value Sales for Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Reovirus, Measles Virus and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Oncolytic Virus Therapy by Application - Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Oncolytic Virus Therapy by Application - Percentage Breakdown of Value Sales for Bladder Cancer, Prostate Cancer, Lung Cancer, Other Applications, Melanoma, Breast Cancer and Head & Neck Cancer for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Oncolytic Virus Therapy by Development Stage - Commercial and Pipeline Phase Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Oncolytic Virus Therapy by Development Stage - Percentage Breakdown of Value Sales for Commercial and Pipeline Phase for the Years 2015, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Oncolytic Virus Therapy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
  • TABLE 418: Africa 15-Year Perspective for Oncolytic Virus Therapy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION